Your browser doesn't support javascript.
loading
Therapeutics and COVID-19: living guideline - 16 September 2022
Geneve; WHO; Sept. 16, 2022. 141 p. ilus, tab, graf. (WHO/2019-nCoV/therapeutics/2022.5).
Non-conventional in English | BIGG, LILACS | ID: biblio-1393164
ABSTRACT
The WHO Therapeutics and COVID-19 living guideline contains the Organization's most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the 'Download' button) and via an online platform, and is updated regularly as new evidence emerges. This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients with severe or critical COVID-19, and modifies previous recommendations for the neutralizing monoclonal antibodies sotrovimab and casirivimab-imdevimab in patients with non-severe COVID-19.

Subject(s)

Full text: Available Index: LILACS (Americas) Main subject: COVID-19 Type of study: Practice guideline Limits: Humans Language: English Year: 2022 Type: Non-conventional

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: COVID-19 Type of study: Practice guideline Limits: Humans Language: English Year: 2022 Type: Non-conventional